Jefferies Group lowered shares of uniQure NV (NASDAQ:QURE) from a buy rating to a hold rating in a research report sent to investors on Monday. They currently have $8.00 target price on the stock, down from their previous target price of $28.00.

Several other equities analysts have also issued reports on QURE. Leerink Swann restated a positive rating and set a $27.00 price target on shares of uniQure NV in a research note on Tuesday, August 2nd. Zacks Investment Research lowered uniQure NV from a hold rating to a sell rating in a research note on Thursday, August 4th. HC Wainwright started coverage on uniQure NV in a research note on Thursday, August 4th. They set a buy rating and a $21.00 price target on the stock. Piper Jaffray Cos. set a $16.00 price target on uniQure NV and gave the company a buy rating in a research note on Friday, August 19th. Finally, Chardan Capital restated a buy rating and set a $12.00 price target (down from $20.00) on shares of uniQure NV in a research note on Tuesday, November 15th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. uniQure NV currently has a consensus rating of Buy and a consensus price target of $22.70.

Analyst Recommendations for uniQure NV (NASDAQ:QURE)

Shares of uniQure NV (NASDAQ:QURE) opened at 6.64 on Monday. The company’s market cap is $166.86 million. uniQure NV has a 52 week low of $6.41 and a 52 week high of $20.22. The firm’s 50-day moving average price is $7.14 and its 200 day moving average price is $8.45.

TRADEMARK VIOLATION WARNING: “uniQure NV (QURE) Downgraded to Hold at Jefferies Group” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/29/uniqure-nv-qure-downgraded-to-hold-at-jefferies-group.html.

Several hedge funds and other institutional investors have recently bought and sold shares of QURE. Point72 Asset Management L.P. increased its position in uniQure NV by 105.7% in the second quarter. Point72 Asset Management L.P. now owns 562,447 shares of the company’s stock worth $4,145,000 after buying an additional 288,982 shares during the period. Baker BROS. Advisors LP bought a new position in uniQure NV during the third quarter worth $1,760,000. Acadian Asset Management LLC bought a new position in uniQure NV during the second quarter worth $804,000. Spark Investment Management LLC increased its position in uniQure NV by 28.5% in the second quarter. Spark Investment Management LLC now owns 380,400 shares of the company’s stock worth $2,803,000 after buying an additional 84,400 shares during the period. Finally, BlackRock Institutional Trust Company N.A. increased its position in uniQure NV by 200.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 70,322 shares of the company’s stock worth $538,000 after buying an additional 46,905 shares during the period. 28.16% of the stock is currently owned by institutional investors.

About uniQure NV

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

5 Day Chart for NASDAQ:QURE

Receive News & Stock Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related stocks with our FREE daily email newsletter.